Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Castle Biosciences and SciBase join forces to create a predictive test for atopic dermatitis flare-ups. Read more here.

Explore how health equity and policy shape outcomes, revealing disparities in kidney disease, atopic dermatitis, and cancer care for vulnerable populations.

Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic DermatitisFRIENDSWOOD, Texas, June 16 ...

Ceramides aren’t just another moisturizer buzzword. From breakthrough lipid blends to ingestible rice-ceramide capsules, ...

With skin cancer on the rise across the UK, Boots is expanding dermatology training for its in-store pharmacists. Matt Nixson tried out its mole-scanning service ...

As surprising as it may sound, your elbows can be more than just joints—they can actually reflect internal health issues. Dry ...

Having a dog at home could help to prevent eczema in children who are genetically prone to the condition, a study suggests.

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.